All Stories

  1. Association Between Homelessness and Mental Healthcare Utilization Among People With Addictions and Mental Health Problems: A Population-Based Study From Alberta Canada
  2. Longitudinal association between income inequality and Canadian adults' psychological distress
  3. Response to Crockford et al .: Healthcare utilization and mortality after overdose prevention site closure: A linked cohort analysis using segmented difference‐in‐differences time series
  4. Reframing Buprenorphine as a Pharmacologic Modifier of Opioid-Induced Respiratory Depression in the Fentanyl Era
  5. Beyond a Moment in Time: Rethinking Capacity and Compassion in Addiction Psychiatry
  6. Addiction, Agency, and the Limits of Choice: Involuntary Care as a Stress Test for Psychiatric Ethics
  7. Defining Cannabis Use Disorder in Administrative Health Data: A Systematic Review of Case Definitions and Validation Approaches
  8. Cannabis Use Disorder in the Era of Legalization: Implications for Addiction Treatment Systems
  9. Healthcare utilization and mortality after overdose prevention site closure: A linked cohort analysis using segmented difference‐in‐differences time series
  10. In the room but not on the byline: trust, fear, and the human role in addiction science in the age of AI
  11. Concurrent Disorders: Treatment of Comorbid Alcohol Use Disorder and Major Depressive Disorder
  12. Long-term, bidirectional associations between depressive symptom severity and opioid use among people with HIV: A prospective cohort study
  13. Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era
  14. The Canadian Network for Mood and Anxiety Treatments Task Force Recommendations for the Use of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplants in Adults With Major Depressive Disorder: Recommandations du Groupe de travail du Réseau...
  15. Characteristics of Adults With Addictions and Mental Health Problems Who Have Experienced Homelessness: A Population-Based Study From Alberta, Canada: Caractéristiques des adultes aux prises avec des problèmes de dépendance et de santé mentale et ayant...
  16. Integrated Management of Co-Occurring Alcohol Use Disorder and Depression: Clinical Approaches for Concurrent Disorders
  17. Emerging pharmacological strategies for the treatment of cannabis use disorder
  18. The Unseen Addiction: Improving Surveillance and Governance of Medical Cannabis in Canada
  19. Treatments for Prolonged Grief Disorder: A Systematic Review and Network Meta-Analysis
  20. Prevalence of Mental Health and Substance Use Disorders Among Adolescents Experiencing Homelessness: A Systematic Review
  21. Beyond first-line approaches: A scoping review of emerging operational stress interventions for military and public safety personnel
  22. Longitudinal effects of neighbourhoods’ material and social deprivation on psychological distress of adults in Canada
  23. Antidepressants in Alcohol Use Disorder: Balancing Evidence, Clinical Nuance, and the Risks of Deprescribing
  24. The Prevalence of Excessive Exercise in Eating Disorders: A Systematic Review and Meta‐Analysis
  25. Quality indicators for substance use disorder care: a scoping review protocol
  26. Limitations and Future Directions in Pharmacological Treatment for Amphetamine-Type Stimulant Use Disorder
  27. Longitudinal Impact of Income Inequality on Canadian Adults’ Psychological Distress
  28. Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities
  29. What Psychiatrists Should Know About Prescribed Safer Opioid Supply
  30. Postdischarge Mortality in a Cohort Hospitalized With Anorexia Nervosa
  31. Prevalence of Mental Health Disorders Among Individuals Experiencing Homelessness
  32. Préoccupations en ce qui concerne la recommandation contre la prescription d’inhibiteurs sélectifs de la recapture de la sérotonine dans laLigne directrice canadienne pour la prise en charge clinique de la consommation d’alcool à risque élevé et du ...
  33. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes ...
  34. Training in Substance use Disorders, Part 1: Overview of Clinical Practice Recommendations
  35. Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
  36. Training in Substance Use Disorders, Part 2: Updated Curriculum Guidelines
  37. Concerns regarding the recommendation against prescribing selective serotonin reuptake inhibitors in the Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder
  38. Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review
  39. Associations between Gender Expression, Protective Coping Strategies, Alcohol Saliency, and High-Risk Alcohol Use in Post-Secondary Students at Two Canadian Universities
  40. Associations between Gender Expression, Protective Coping Strategies, Alcohol Saliency, and High-Risk Alcohol Use in Post-Secondary Students at Two Canadian Universities
  41. Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis
  42. Evidence base to support using prescribed psychostimulants to treat psychostimulant use disorder is limited
  43. Navigating Evidence, Challenges, and Caution in the Treatment of Stimulant Use Disorders
  44. Implications of Cannabis Legalization on Substance-Related Benefits and Harms for People Who Use Opioids: A Canadian Perspective
  45. Cannabis use disorder and adverse cardiovascular outcomes: A population‐based retrospective cohort analysis of adults from Alberta, Canada
  46. The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
  47. Ketamine for the treatment of major depression: a systematic review and meta-analysis
  48. Ways to get a more balanced gender representation in addiction journals’ management and workforce
  49. Cases: Multiorgan failure in a 38-year-old man with recent consumption of kratom, an atypical opioid
  50. The Effectiveness of Inpatient Addiction Consult Services: A Systematic Review and Narrative Synthesis
  51. Involuntary Treatment for Adult Nonoffenders With Substance Use Disorders?
  52. Guilty until proven innocent
  53. Response to “Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.”
  54. Factors Associated with Bothersome Symptoms in Individuals With and Without HIV Who Report Alcohol Use
  55. Assessing research competency development in Canadian psychiatry residency programs: A systematic review and future directions
  56. Ketamine for the Treatment of Major Depression: A Systematic Review and Meta-Analysis
  57. Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis
  58. Association Between Substance Use and Professional Outcomes Among Medical Students: Findings from a Canadian Cross-sectional Survey
  59. Managing Comorbid Tobacco Use Disorder for Individuals With Schizophrenia: Challenges and Opportunities
  60. Letter to the Editor: Cannabis as a Solution to the Opioid Crisis: Is the Cart Before the Horse Again?
  61. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies
  62. Managing Adult Attention-deficit/Hyperactivity Disorder With Comorbid Substance Use Disorder
  63. Psychological interventions for post-traumatic stress injuries among public safety personnel: a systematic review and meta-analysis
  64. Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis
  65. The Rise, Fall, and Resurgence of Electroconvulsive Therapy
  66. The Rising Tide of Stimulant-Related Morbidity and Mortality Warrants Evidence-Based Treatment
  67. Correction: Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis
  68. The critical role of peer reviewers: Challenges and future steps
  69. Factors Associated With Past-year and Lifetime Prevalence of Cannabis Withdrawal: A Secondary Analysis
  70. Trends in Canadian Cannabis Consumption Over Time: A Two-step Meta-analysis of Canadian Household Survey Data
  71. Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis
  72. Management of Post-Acute Alcohol Withdrawal: A Mixed-Studies Scoping Review
  73. Neurobiology and Symptomatology of Post-Acute Alcohol Withdrawal: A Mixed-Studies Systematic Review
  74. Exclusion of the non-English-speaking world from the scientific literature: Recommendations for change for addiction journals and publishers
  75. Challenges and opportunities for further research involving the cannabis‐to‐opioid use transition
  76. Alien Hand Syndrome in Lewy Body Dementia
  77. Self-Reported Cannabis Use and HIV Viral Control among Patients with HIV Engaged in Care: Results from a National Cohort Study
  78. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta‐analysis
  79. Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review
  80. Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
  81. Comment on “I’m Virtually a Psychiatrist: Problems with Telepsychiatry in Training”
  82. Patients With Infective Endocarditis Deserve Evidence-based Addiction Treatment
  83. Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders
  84. Office-based Methadone Prescribing for Opioid Use Disorder: The Canadian Model
  85. The Prevalence of Impulse Control Disorders and Behavioral Addictions in Eating Disorders: A Systematic Review and Meta-Analysis
  86. Considering Cannabis Use in Differential Diagnosis
  87. Listening to the Patient's Voice: A Patient-Centred Approach to Treatment-Resistant Schizophrenia
  88. Prevalence And Definitions of Polypharmacy: A Systematic Review And Meta-Analysis
  89. The prevalence of substance use disorders and substance use in anorexia nervosa: a systematic review and meta-analysis
  90. Opioid Use Disorder Comorbidity in Individuals With Schizophrenia-Spectrum Disorders: A Systematic Review and Meta-Analysis
  91. Strategies to aid self‐isolation and quarantine for individuals with severe and persistent mental illness during the COVID‐19 pandemic: A systematic review
  92. Prevalence of and Factors Associated With Substance Use Among Canadian Medical Students
  93. What are the clinical implications of Bahá’í perspectives of psychiatry and mental health?
  94. Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis
  95. Genetic markers of the stress generation model: A systematic review
  96. Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis
  97. Concurrent Disorders Management in Psychiatric Care: Opportunities and Challenges
  98. The Prevalence of Cannabis Use Disorder Comorbidity in Individuals With Bipolar Disorder: A Systematic Review and Meta-Analysis
  99. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium
  100. Supporting Persons Who Use Drugs During the COVID-19 Pandemic: A Rapid Review of International Guidelines
  101. Towards competency-based medical education in addictions psychiatry: a systematic review
  102. Ketamine for Bipolar Depression: A Systematic Review
  103. Proactive psychological programs designed to mitigate posttraumatic stress injuries among at-risk workers: a systematic review and meta-analysis
  104. Comparative Efficacy and Acceptability of Psychotherapies for Self-harm and Suicidal Behavior Among Children and Adolescents
  105. Making a case for the inclusion of refractory and severe mental illness as a sole criterion for Canadians requesting medical assistance in dying (MAiD): a review
  106. Misuse and dependence of dimenhydrinate: A mixed studies systematic review
  107. Transcranial direct current stimulation for empathy: A systematic review and meta-analysis
  108. Psychological interventions for posttraumatic stress injuries among public safety personnel: a systematic review and meta-analysis
  109. Coping among public safety personnel: A systematic review and meta–analysis
  110. Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?
  111. Policy Brief: CSAM in Support of the Decriminalization of Drug Use and Possession for Personal Use
  112. Recent Advances in Biomarkers of Addiction: A Narrative Review
  113. Erratum to “Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis” [Journal of Affective Disorders 278C (2021) 542–555]
  114. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
  115. Response to Canadian Psychiatric Association Cannabinoid Products Position Statement: Potential for Ameliorating Cannabis Withdrawal
  116. Alcohol-Related Psychiatric Presentations at a University-Affiliated Emergency Department: A Descriptive Prevalence Study
  117. Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis
  118. COVID-19 and the Need for Leadership Training in Psychiatry
  119. The Substance Treatment and Recovery Team (START): Measuring the effectiveness and feasibility of an inpatient addiction consult service at an academic general hospital
  120. Efficacy and acceptability of cannabinoids for anxiety disorders in adults: A systematic review & meta-analysis
  121. The Addictive Nature of Compulsive Sexual Behaviours and Problematic Online Pornography Consumption: A Review
  122. Response to Canadian Psychiatric Association Opioid Use Disorder Position Statement: More than Just Collaborators in Care
  123. The Impact of Community Treatment Orders on Substitute Decision Makers
  124. Predictors of hospital admission for patients presenting with psychiatric emergencies: A retrospective, cohort study
  125. Virtual psychiatric care for older adults in the age of COVID‐19: Challenges and opportunities
  126. How to Serve the Underserved: Making the Case for Rural and Remote Mental Health Training for Psychiatry Residents
  127. Five-Year Follow-Up for Adolescents With Conduct Disorder Referred to an Urgent Psychiatric Consult Clinic
  128. Harm Reduction for Injection Drug Users with Infective Endocarditis: A Systematic Review
  129. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis
  130. Effectiveness of Pharmacotherapies for Bipolar Depression: A Systematic Review & Network Meta-Analysis
  131. Incidence and correlates of opioid-related psychiatric emergency care: A retrospective, multiyear cohort study
  132. Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids
  133. Incidence and Correlates of Cannabinoid-Related Psychiatric Emergency Care: A Retrospective, Multiyear Cohort Study
  134. Methamphetamine-Related Emergency Department Visits Requiring Psychiatric Admission: A Retrospective Cohort Study
  135. Mortality Among People With Opioid Use Disorder: A Systematic Review and Meta-analysis
  136. Commentary on Hayes et al. (2020): The harms of opioid dose escalation in the management of chronic non‐cancer pain
  137. Acknowledgement to Reviewers of JCM in 2019
  138. Acceptability and efficacy of naltrexone for criminal justice‐involved individuals with opioid use disorder: a systematic review and meta‐analysis
  139. Systematic Review and Meta-Analyses of Psychotherapies for Adolescents with Subclinical and Borderline Personality Disorder: A Reply to the Commentary by Jørgensen, Storebø, and Simonsen
  140. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis
  141. Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis
  142. Prevalence of intimidation, harassment, and discrimination in resident physicians: a systematic review and meta-analysis
  143. At-a-glance - The local response to the Canadian opioid epidemic in the Kingston, Frontenac, and Lennox and Addington communities
  144. 2.62 PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADOLESCENTS WITH SUBCLINICAL AND BORDERLINE PERSONALITY DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS
  145. Psychotherapies for Adolescents with Subclinical and Borderline Personality Disorder: A Systematic Review and Meta-Analysis
  146. Reduction in mortality risk with opioid agonist therapy: a systematic review and meta‐analysis
  147. International Perspectives on the Implications of Cannabis Legalization: A Systematic Review & Thematic Analysis
  148. What are the key considerations for clinicians treating Bahá'í patients with psychiatric disorders?
  149. Commentary on Stockings et al . (2019): The global amphetamine epidemic — a rising tide of mortality
  150. The Value of Hospitalization in the Opioid Epidemic
  151. On the Relative Impact of Substances in Canada
  152. Is stigma preventing knowledge translation and utilization of electroconvulsive therapy for depression?
  153. Management of endocarditis among persons who inject drugs: A narrative review of surgical and psychiatric approaches and controversies
  154. Piloting an Addictions Medicine Consultation Team in Kingston, Ontario, Canada
  155. Prevalence of substance use disorder comorbidity among individuals with eating disorders: A systematic review and meta-analysis
  156. Characterizing inpatient care for adults with schizophrenia using the Health Quality Ontario indices: A single-centre retrospective cohort study
  157. A Critical Review of Addictions Curriculum in Canadian Residency Programs
  158. ECT beyond unipolar major depression: systematic review and meta‐analysis of electroconvulsive therapy in bipolar depression
  159. The Emerging Epidemic of Male Me-Too
  160. Attitudes to antipsychotics: a multi-site survey of Canadian psychiatry residents
  161. Assessing the utility of drug screening in the emergency: a short report
  162. Episodic Behavioural Regression in an 8-Year-Old Female: Sequelae of 22q11.2 Duplication Syndrome
  163. A case for opioid education and training for medical students, residents, and allied health staff: response to “educational intervention for physicians to address the risk of opioid abuse”
  164. Endocarditis in the setting of IDU
  165. Opioids on Trial
  166. Why residents need more training in prescribing antipsychotics for people with Schizophrenia
  167. Increasing awareness about HIV prevention among young people who initiated injection drug use in a Canadian setting, 1988–2014